A prospective feasibility study of radiation and concurrent bevacizumab for recurrent endometrial cancer
| Autor: | Suzanne Berlin, Ursula A. Matulonis, Neil S. Horowitz, Cheryl A. Sadow, Michael G. Muto, Ross S. Berkowitz, Colleen M. Feltmate, Hang Lee, S. M. Campos, Akila N. Viswanathan |
|---|---|
| Rok vydání: | 2014 |
| Předmět: |
Oncology
medicine.medical_specialty Bevacizumab Angiogenesis Inhibitors Disease Antibodies Monoclonal Humanized Disease-Free Survival Internal medicine medicine Humans Prospective Studies Aged Aged 80 and over business.industry Endometrial cancer Obstetrics and Gynecology Cancer Chemoradiotherapy Middle Aged medicine.disease Thrombosis Endometrial Neoplasms Regimen Lymphatic Metastasis Toxicity Feasibility Studies Female Ovarian cancer business medicine.drug |
| Zdroj: | Gynecologic Oncology. 132:55-60 |
| ISSN: | 0090-8258 |
| DOI: | 10.1016/j.ygyno.2013.10.031 |
| Popis: | Objectives To determine the toxicity and survival rates in a trial of concurrent bevacizumab and external beam radiation (EB) for patients with recurrent endometrial or ovarian cancer. Methods Nineteen women with recurrent endometrial ( n =15) or ovarian ( n =4) cancer with gross disease involving the vaginal cuff, and/or pelvic nodes and/or para-aortic nodes, cancer were enrolled between 2008 and 2010. All patients received bevacizumab during radiation. Toxicity was assessed at baseline, weekly during treatment and every 3months for at least 1year after treatment. Results All patients completed EB on schedule. For the 15 patients with recurrent endometrial cancer, the 1- and 3-year progression-free survival (PFS was) 80%/67% and overall survival (OS) was 93%/80%. Patients that had a vaginal cuff recurrence alone had a 1- and 3-year PFS of 75%/63% and OS of 100%/75%. Two patients with pelvic node involvement did not recur throughout the entire follow-up period. The 5 patients with para-aortic node involvement had a 1- and 3-year PFS of 80%/60% and OS of 80%/80%. Of the 4 ovarian cancer patients 3 relapsed with 1- and 3-year PFS of 80%/40% and OS of 100%/60%. Toxicities included thrombosis and 1 embolic event in the setting of metastastic disease. No gastrointestinal perforations were noted. Conclusions Delivering bevacizumab with concurrent radiation provides excellent local tumor control and survival for women with recurrent endometrioid endometrial cancer, particularly those with unresectable nodes. Caution must be used in those at highest risk of developing metastatic disease given the increased risk of thromboembolic events. This regimen may be considered for recurrent gynecologic malignancies in future trials. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect